Details of the Drug Reposition

General Information of This Drug (ID: DM3G74J)

Drug Name
Tamibarotene   DM3G74J
Synonyms Tamibarotene (oral, Alzheimer's disease)
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
T-cell leukaemia DISJ6YIF 2A90 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 2/3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Alzheimer disease DISF8S70 8A20 Phase 2/3 [2]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Promyelocytic leukaemia DISYGG13 2A82.1 Discontinued in Phase 3 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04797780) SY-1425 Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome. U.S. National Institutes of Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2648).
3 Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population